Skip to main content

Table 1 Baseline characteristics

From: Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

Variables

Sedentary group (n = 31)

Active group

(n = 28)

P value

Age (years), mean ± SD

55.9 ± 12.4

53.5 ± 8.1

0.387

Gender

 Male

26 (83.9%)

27 (96.4%)

0.245

 Female

5 (16.1%)

1 (3.6%)

PS score

 0

12 (38.7%)

18 (64.3%)

0.050

 1

19 (61.3%)

10 (35.7%)

Overweight

 No

30 (96.8%)

26 (92.9%)

0.599

 Yes

1 (3.2%)

2 (7.1%)

Child–Pugh classification

 A

30 (96.8%)

27 (96.4%)

1.000

 B

1 (3.2%)

1 (3.6%)

BCLC stage

 A

1 (3.2%)

3 (10.7%)

0.520

 B

7 (22.6%)

6 (21.4%)

 C

23 (74.2%)

19 (67.9%)

CNLC stage

 I

1 (3.2%)

3 (10.7%)

0.520

 II

7 (22.6%)

6 (21.4%)

 III

23 (74.2%)

19 (67.9%)

Tumor size (cm), mean ± SD

12.3 ± 5.5

10.7 ± 5.8

0.351

Extra-hepatic metastasis

 No

26 (83.9%)

21 (75.0%)

0.398

 Yes

5 (16.1%)

7 (25.0%)

Macrovascular invasion

 No

11 (35.5%)

14 (50.0%)

0.260

 Yes

20 (64.5%)

14 (50.0%)

WBC (× 109/L), mean ± SD

5.8 ± 2.0

5.7 ± 1.9

0.828

NLR, mean ± SD

3.3 ± 1.6

2.7 ± 1.2

0.124

TB (μmol/L), mean ± SD

17.5 ± 9.6

16.7 ± 7.6

0.753

ALB (g/L), mean ± SD

38.5 ± 5.8

41.6 ± 4.0

0.020

ALT (U/L), mean ± SD

42.0 ± 26.3

40.8 ± 24.7

0.856

AST (U/L), mean ± SD

73.7 ± 68.4

51.6 ± 34.8

0.130

GGT (U/L), mean ± SD

234.9 ± 223.9

183.3 ± 211.8

0.368

INR, mean ± SD

1.2 ± 0.1

1.1 ± 0.1

0.092

AFP (ng/mL)

 < 400

13 (41.9%)

11 (39.3%)

0.836

  ≥ 400

18 (58.1%)

17 (60.7%)

DCP (mAU/mL)

  < 400

3 (9.70%)

10 (35.7%)

0.036

  ≥ 400

28 (90.3%)

18 (64.3%)

HBsAg

 – 

05 (16.1%)

6 (21.4%)

0.602

  + 

26 (83.9%)

22 (78.6%)

Antiviral therapies

 Entecavir

22 (84.6%)

18 (81.8%)

0.796

 Tenofovir disoproxil fumarate

4 (15.4%)

4 (18.2%)

HBV-DNA (IU/mL)

 ≤ 1000

13 (41.9%)

21 (75.0%)

0.010

  > 1000

18 (58.1%)

7 (25.0%)

  1. AFP alpha-fetoprotein ,ALB albumin, ALT alanine transaminase, AST aspartate transaminase, BCLC Barcelona Clinic Liver Cancer, CNLC China Liver Cancer, DCP des-γ-carboxy prothrombin, GGT gamma-glutamyl transpeptidase, HBV hepatitis B virus, HbsAg hepatitis B surface antigen, INR international normalized ratio, NLR neutrophil–lymphocyte ratio, PS performance status, TB total bilirubin, WBC white blood count